Skip to main content

Starling Oncology, Inc 10-Q for FY2026 Q3

Starling Oncology, Inc. (STLN)

10-Q 2026-11-06 For: 2026-09-30
View Original
Added on November 06, 2026

About this 10-Q

Starling Oncology, Inc filed this 10-Q on November 6, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Starling Oncology reported third-quarter revenue of $169,767 and net loss of $(15,748), with figures in thousands; Adjusted EBITDA was $3,394. At September 30, 2026, cash was $36,895, and management expected liquidity for at least one year. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$169.77M
up 24.3% from $136.56M a year earlier
Net loss
$15.75M
compared with a net loss of $16.5M a year earlier
Diluted EPS
-$0.13
compared with -$0.14 a year earlier